Malaria, Falciparum

Infectious Diseases
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax MalariaPhase 21 trial
Active Trials
NCT04709692Completed22Est. Apr 2022
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
Methylene BluePhase 21 trial
Active Trials
NCT02851108Completed100Est. Feb 2017
QT
Q TherapeuticsUT - Salt Lake City
1 program
1
MMV390048 20mgPhase 11 trial
Active Trials
NCT02281344TerminatedEst. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiEfficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Heidelberg PharmaMethylene Blue
Q TherapeuticsMMV390048 20mg

Clinical Trials (3)

Total enrollment: 122 patients across 3 trials

NCT04709692EisaiEfficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

Start: Apr 2021Est. completion: Apr 202222 patients
Phase 2Completed

Methylene Blue Against Falciparum Malaria in Burkina Faso

Start: Oct 2016Est. completion: Feb 2017100 patients
Phase 2Completed

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Start: Oct 2014Est. completion: Dec 2014
Phase 1Terminated

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space